Teladoc Health, Inc. (TDOC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Teladoc Health, Inc. (TDOC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 24, 2026, Mr. Adam C. Vandervoort, Chief Legal Officer and Secretary of Teladoc Health, Inc. (the "Company"),
How this was made
The 30-second read
Why it matters
The filing provides the first public notice of the leadership change, which may affect investor perception of governance stability.
Market read
Primary disclosure of an officer departure; modest trading relevance for TDOC.
What to watch
Potential hidden legal disputes or restructuring plans tied to the leadership change.
Background
SEC Form 8‑K filing discloses the resignation of Teladoc's Chief Legal Officer and the appointment of a successor.
Ticker impact
Chief Legal Officer Adam C. Vandervoort resigns effective Nov 1, 2026; Jonathan Dorfman appointed as successor.
Potential modest dip or sideways movement pending market reaction.
Leadership change is material for governance but does not alter earnings or cash flow.
Market effects
Minimal impact on telehealth sector; similar firms may see slight attention to governance.
U.S. market only; no broader regional effect.
Low global relevance.
Counterpoint
The resignation could be a catalyst for a strategic shift that investors undervalue.
Key entities
- CompanyTeladoc Health, Inc.
U.S. listed telehealth provider (ticker TDOC).
- ExecutiveAdam C. Vandervoort
Outgoing Chief Legal Officer and Secretary.
- ExecutiveJonathan Dorfman
Appointed new Chief Legal Officer and Secretary.
